1. Home
  2. TETE vs BYSI Comparison

TETE vs BYSI Comparison

Compare TETE & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TETE
  • BYSI
  • Stock Information
  • Founded
  • TETE 2021
  • BYSI 2010
  • Country
  • TETE Malaysia
  • BYSI United States
  • Employees
  • TETE N/A
  • BYSI N/A
  • Industry
  • TETE Blank Checks
  • BYSI Biotechnology: Pharmaceutical Preparations
  • Sector
  • TETE Finance
  • BYSI Health Care
  • Exchange
  • TETE Nasdaq
  • BYSI Nasdaq
  • Market Cap
  • TETE 73.0M
  • BYSI 68.5M
  • IPO Year
  • TETE 2022
  • BYSI 2017
  • Fundamental
  • Price
  • TETE $12.30
  • BYSI $1.63
  • Analyst Decision
  • TETE
  • BYSI
  • Analyst Count
  • TETE 0
  • BYSI 0
  • Target Price
  • TETE N/A
  • BYSI N/A
  • AVG Volume (30 Days)
  • TETE 8.9K
  • BYSI 28.4K
  • Earning Date
  • TETE 01-01-0001
  • BYSI 01-01-0001
  • Dividend Yield
  • TETE N/A
  • BYSI N/A
  • EPS Growth
  • TETE N/A
  • BYSI N/A
  • EPS
  • TETE 0.02
  • BYSI N/A
  • Revenue
  • TETE N/A
  • BYSI $1,876,000.00
  • Revenue This Year
  • TETE N/A
  • BYSI N/A
  • Revenue Next Year
  • TETE N/A
  • BYSI N/A
  • P/E Ratio
  • TETE $699.42
  • BYSI N/A
  • Revenue Growth
  • TETE N/A
  • BYSI 21.03
  • 52 Week Low
  • TETE $11.37
  • BYSI $0.78
  • 52 Week High
  • TETE $12.32
  • BYSI $4.00
  • Technical
  • Relative Strength Index (RSI)
  • TETE 68.58
  • BYSI 40.58
  • Support Level
  • TETE $12.21
  • BYSI $1.55
  • Resistance Level
  • TETE $12.32
  • BYSI $1.84
  • Average True Range (ATR)
  • TETE 0.02
  • BYSI 0.19
  • MACD
  • TETE 0.01
  • BYSI 0.00
  • Stochastic Oscillator
  • TETE 84.62
  • BYSI 10.96

About TETE Technology & Telecommunication Acquisition Corporation

Technology & Telecommunication Acquisition Corp is a blank check company.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.

Share on Social Networks: